The Oncology Institute (The Oncology Institute) Gross Margin % : 12.64% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is The Oncology Institute Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. The Oncology Institute's Gross Profit for the three months ended in Mar. 2024 was $12.0 Mil. The Oncology Institute's Revenue for the three months ended in Mar. 2024 was $94.7 Mil. Therefore, The Oncology Institute's Gross Margin % for the quarter that ended in Mar. 2024 was 12.64%.

Warning Sign:

The Oncology Institute Inc gross margin has been in long-term decline. The average rate of decline per year is -2.7%.

The historical rank and industry rank for The Oncology Institute's Gross Margin % or its related term are showing as below:

TOI' s Gross Margin % Range Over the Past 10 Years
Min: 16.76 Med: 19.9 Max: 23.23
Current: 16.76

During the past 6 years, the highest Gross Margin % of The Oncology Institute was 23.23%. The lowest was 16.76%. And the median was 19.90%.

TOI's Gross Margin % is ranked worse than
86.21% of 609 companies
in the Healthcare Providers & Services industry
Industry Median: 41.54 vs TOI: 16.76

The Oncology Institute had a gross margin of 12.64% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for The Oncology Institute was -2.70% per year.

The Oncology Institute Gross Margin % Historical Data

The historical data trend for The Oncology Institute's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Oncology Institute Gross Margin % Chart

The Oncology Institute Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

19.27

19.67

20.12

20.63

18.37

The Oncology Institute Quarterly Data
	Sep18	Dec18	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross Margin %	Get a 7-Day Free Trial														18.50	18.84	19.48	16.76	12.64

Competitive Comparison of The Oncology Institute's Gross Margin %

For the Medical Care Facilities subindustry, The Oncology Institute's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

The Oncology Institute's Gross Margin % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's Gross Margin % distribution charts can be found below:

* The bar in red indicates where The Oncology Institute's Gross Margin % falls into.

The Oncology Institute Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

The Oncology Institute's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	59.6	/	324.239
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(324.239 - 264.666)	/	324.239
	=	18.37 %

The Oncology Institute's Gross Margin for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )	=	Gross Profit (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	12	/	94.666
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(94.666 - 82.697)	/	94.666
	=	12.64 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

The Oncology Institute (NAS:TOI) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

The Oncology Institute had a gross margin of 12.64% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

The Oncology Institute Gross Margin % Related Terms

Thank you for viewing the detailed overview of The Oncology Institute's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

The Oncology Institute (The Oncology Institute) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » The Oncology Institute Inc (NAS:TOI) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703

Website

https://www.theoncologyinstitute.com

The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.

Executives

Havencrest Healthcare Partners, L.p.	10 percent owner	5221 N. O'CONNOR BLVD., SUITE 1200, IRVING TX 75039
Mihir Shah	officer: Chief Financial Officer, other: Principal Financial Officer	C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801
Brad Hively	director, officer: Chief Executive Officer	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Jeremy Castle	officer: Chief Operating Officer	1800 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Richard A Barasch	director, officer: Executive Chairman	C/O UNIVERSAL AMERICAN FINANCIAL CORP, SIX INTERNATIONAL DRIVE SUITE 190, RYE BROOK NY 10573
Matthew P Miller	officer: Chief Operating Officer	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Daniel Virnich	officer: Chief Operating Officer	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Yale Podnos	officer: Chief Medical Officer	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Diona Simoneit	officer: Chief Accounting Officer, other: Principal Accounting Officer	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Mohit Kaushal	director	44 SOUTH BROADWAY, WHITE PLAINS NY 10601
Gabriel Ling	director	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Mark L Pacala	director	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Richy Agajanian	10 percent owner	C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Maeve O'meara	director	C/O CASTLIGHT HEALTH, INC., 150 SPEAR ST., SUITE 400, SAN FRANCISCO CA 94105
Toi Hc I, Llc	10 percent owner	2100 MCKINNEY AVENUE, SUITE 1760, DALLAS TX 75201